Exagen to Announce Fourth Quarter and Full Year Financial Results on March 16, 2021
March 02, 2021 08:00 ET
|
Exagen Inc.
SAN DIEGO, March 02, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading autoimmune organization, will release financial results for the quarter and year ended December 31, 2020 after the...
Exagen Inc. to Participate in the Cowen 41st Annual Health Care Conference
February 22, 2021 16:05 ET
|
Exagen Inc.
SAN DIEGO, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading autoimmune organization, today announced its participation in the Cowen 41st Annual Health Care Conference which...
Equillium to Present at the SVB Leerink 10th Annual Global Healthcare Conference
February 18, 2021 08:00 ET
|
Equillium
LA JOLLA, Calif., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders,...
Equillium Presents Positive Interim Clinical Data of Itolizumab in First-line Treatment of Acute Graft-Versus-Host Disease at the 2021 Transplantation and Cellular Therapy Meetings Digital Experience
February 12, 2021 15:00 ET
|
Equillium
Higher dose cohorts demonstrated 100% overall response rate, resulting in substantial reduction in baseline corticosteroid use Dose-dependent reduction of CD6 expression on CD4+ and CD8+ T cells is...
Equillium Announces the Appointment of Katherine Xu to the Board of Directors
February 09, 2021 08:00 ET
|
Equillium
LA JOLLA, Calif., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ) a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders,...
Exagen Inc. To Participate in BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
February 03, 2021 16:05 ET
|
Exagen Inc.
SAN DIEGO, Feb. 03, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading autoimmune organization, today announced its participation in the BTIG MedTech, Digital Health, Life Science &...
Exagen Inc. Reports Preliminary Fourth Quarter 2020 Testing Results
January 10, 2021 18:00 ET
|
Exagen Inc.
Record Testing Revenue, Adopters and AVISE CTD® Volumes SAN DIEGO, Jan. 10, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for...
Exagen Inc. To Participate in 2021 ICR Conference
January 05, 2021 16:05 ET
|
Exagen Inc.
SAN DIEGO, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, announced today...
Equillium to Present at the H.C. Wainwright Virtual BioConnect Conference
January 05, 2021 08:00 ET
|
Equillium
LA JOLLA, Calif., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ) a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders,...
Exagen Inc. Partners with Oregon’s St. Charles Health System to Offer AVISE® Testing as an In-Network Benefit for Patients Suffering from Debilitating Autoimmune Diseases
January 04, 2021 16:05 ET
|
Exagen Inc.
SAN DIEGO, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, announced today...